Cancer research groups push emergency funding to restart clinical trials in infrastructure package

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

A group of more than 50 cancer research-focused organizations are urging Congress to include $10 billion in emergency funding to restart cancer research and clinical trials at the National Institutes of Health stalled by the coronavirus pandemic.

In a letter sent to lawmakers, members of the One Voice Against Cancer coalition say without the additional resources in the forthcoming American Jobs Plan, promising research will languish and potentially be lost entirely.

“The pandemic’s impact on cancer research has been severe. Early shutdowns forced research to come to an abrupt halt, and restarting trials has required implementing new protocols, procuring personal protective equipment and sometimes restarting work altogether that otherwise could not be resumed,” Lisa Lacasse, president of the American Cancer Society Cancer Action Network, said in a statement. “The cost of these disruptions has been significant and threatens to jeopardize progress in the effort to reduce our country’s cancer burden for years to come.”

“Clinical trials are often the best and sometimes only course of treatment for patients in need of care. On behalf of all cancer patients, survivors and their families, we urge Congress to include this additional NIH funding in the American Jobs Plan and ensure medical research can keep moving forward without delay.”

Table of Contents

YOU MAY BE INTERESTED IN

Candace S. Johnson leads America’s oldest cancer research center and Jonathan W. Friedberg leads the newest NCI-designated center. Their catchment areas are contiguous, their faculty and staff members collaborate often, and together their institutions embody the culture of NCI-designated cancer centers. 

In the first meeting of the National Cancer Advisory Board since the inauguration of President Donald Trump, NCI Principal Deputy Director Douglas R. Lowy addressed many of the burning questions the oncology field has for the institute. On indirect costs: NCI will continue to use previously negotiated and approved indirect cost rates, with the exception...

The Cancer Letter staff were finalists for nine 2025 Dateline Awards from the Washington, D.C. Chapter of the Society of Professional Journalists—seven for journalism; two for design—and won first place for four. The Cancer Letter’s entries recognized by SPJ include investigative journalism, series, breaking news, features, photojournalism, commentary, illustration, and front page design. This is...

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login